DD Should Transfer Part of Breast Cancer $$ To NIH r Peer Distribution, Broder Says
In Brief: McDonough Leaves Komen Foundation; Henderson To Head Salk Institute; Alabama Recruits Two
NCI to Ask Cancer Panel, NCAB, to Help Respond To Request for Review Of National Cancer Program
Final stats On FY92 Budget; Success Rate Was 35 Percent
DCBDC Bard Approves Expansion Of SPORE Program To GY Cancers; Okays Two other RFAs
NCI to Recompete contracts for Frederick
NIH Funding Strategies, UICC Fellowships
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
